Business Description
iBio Inc
NAICS : 325412
SIC : 2834
ISIN : US4510332038
Total Employee Number:
20Description
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 40.05 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.48 | |||||
Beneish M-Score | 33.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 81.1 | |||||
3-Year EPS without NRI Growth Rate | 82.2 | |||||
3-Year FCF Growth Rate | 84.3 | |||||
3-Year Book Growth Rate | -53.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -19.56 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -40.55 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.3 | |||||
9-Day RSI | 26.11 | |||||
14-Day RSI | 32.87 | |||||
3-1 Month Momentum % | -25.83 | |||||
6-1 Month Momentum % | -47.61 | |||||
12-1 Month Momentum % | 74.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.85 | |||||
Quick Ratio | 7.85 | |||||
Cash Ratio | 7.5 | |||||
Days Sales Outstanding | 237.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -279.9 | |||||
Shareholder Yield % | -2.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -30138 | |||||
Net Margin % | -33044 | |||||
EBITDA Margin % | -31961 | |||||
FCF Margin % | -24077.65 | |||||
OCF Margin % | -23496.47 | |||||
ROE % | -56.83 | |||||
ROA % | -49.07 | |||||
ROIC % | -230.12 | |||||
3-Year ROIIC % | 3.25 | |||||
ROC (Joel Greenblatt) % | -644.61 | |||||
ROCE % | -54.92 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 660 | |||||
PB Ratio | 0.86 | |||||
Price-to-Tangible-Book | 0.87 | |||||
EV-to-EBIT | 0.05 | |||||
EV-to-EBITDA | 0.05 | |||||
EV-to-Revenue | -15.98 | |||||
EV-to-Forward-Revenue | 473.26 | |||||
EV-to-FCF | 0.04 | |||||
| Price-to-Net-Current-Asset-Value | 0.93 | |||||
| Price-to-Net-Cash | 0.99 | |||||
Earnings Yield (Greenblatt) % | 1991.78 | |||||
FCF Yield % | -28.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
iBio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.085 | ||
| EPS (TTM) (€) | -0.284 | ||
| Beta | 1.2734 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.1 | ||
| Volatility % | 133.6 | ||
| 14-Day RSI | 32.87 | ||
| 14-Day ATR (€) | 0.031504 | ||
| 20-Day SMA (€) | 1.1697 | ||
| 12-1 Month Momentum % | 74.89 | ||
| 52-Week Range (€) | 0.615 - 2.62 | ||
| Shares Outstanding (Mil) | 64.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
iBio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
iBio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-10 | In 160 days | ||
| General meeting for 2026 | 2026-11-20 13:00 | In 79 days | ||
| First quarter earnings results for 2027 | 2026-11-12 16:01 | In 71 days | ||
| Annual report for 2026 | 2026-08-28 | 1.18 (+0.00%) | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | 1.18 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:40 | 1.46 (-0.27%) | ||
| Third quarter earnings results for 2026 | 2026-05-12 | 1.40 (+0.00%) | ||
| iBio Provides Update on Cardiopulmonary Program Targeting PH-HfpEF | 2026-03-17 16:00 | 2.10 (+0.00%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 16:20 | 2.22 (+0.00%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 14:00 | 2.04 (+0.00%) |
Show
Entries
iBio Inc Frequently Asked Questions
What is iBio Inc(FRA:0JV0)'s stock price today?
The current price of FRA:0JV0 is €1.04. The 52 week high of FRA:0JV0 is €2.62 and 52 week low is €0.62.
When is next earnings date of iBio Inc(FRA:0JV0)?
The next earnings date of iBio Inc(FRA:0JV0) is 2026-11-12 Est..
Does iBio Inc(FRA:0JV0) pay dividends? If so, how much?
iBio Inc(FRA:0JV0) does not pay dividend.
Press Release
Articles on iBio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers